Pharsight awarded patent on graphical method for creating drug models

By E. Janene Geiss

Philadelphia, May 18 - Pharsight Corp. said Thursday that it has been awarded a patent for interactively building pharmacokinetic and pharmacodynamic models using a graphical interface.

The patented graphical interface is already deployed in Pharsight Trial Simulator, according to a company news release.

"The Food and Drug Administration's Critical Path Initiative calls for more PK/PD modeling to streamline drug development and approval," said Shawn O'Connor, president, chief executive and chairman of Pharsight, in the release.

"The graphical and intuitive interface covered by our patent ... allows [companies] to achieve increased modeling productivity," he added.

The graphical user interface allows users to place and connect objects representing pharmacokinetic and pharmacodynamic elements. As the objects are placed and connected, they are converted into an internal format representing the statements of the corresponding computational model, officials said.

These statements are actively presented to the user in a summarized form, as the computational model is constructed, to enable immediate verification of the model.

This summarized form may be a surface syntax showing key equations that make up the model, or they may be graphs of behavior of one or more user-selected variables, officials said.

Pharsight, based in Mountain View, Calif., makes integrated products and services that enable pharmaceutical and biotechnology companies to achieve improvements in development of therapeutic products.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.